Navigation Links
Presence of substandard drugs can pose concern for patients,,

German scientists have found out that the drug streptokinase used in many non-European countries //are not up to the standard, as the amount of streptokinase present in the preparation is really low.

The study, which had tested 16 different forms of streptokinase medications across the European continent, has found only three formulations that match the safety and quality standards.

The drug streptokinase is used for its anti-clotting effect and if administered after a cardiac arrest, it can increase the chances of survival by over 25%.

The study showed that medications could only realize the claims that had been made in their labels by as high as 90% to as low as 20% in some cases. These drugs are sold in countries like Brazil, India, Jordan, China and Pakistan. The report which comes out in the latest issue of the journal Circulation has once again raised the question of substandard drugs being marketed at countries where the healthcare industry is not so stringent on the quality of the medications marketed.

Researchers are of the opinion that the cases of counterfeit medications are high in the countries where the disease incidence is high and the public monitoring system is under pressure. However it still remains important that our country takes additional steps to monitor the problem of counterfeit drugs.
'"/>




Page: 1

Related medicine news :

1. Tamoxifen Ineffective In Presence Of Genetic Variation in Breast Cancer
2. Haj Pilgrims Being Tested For Presence Of Bird Flu Infection
3. Presence Of Live Avian Flu Is A Cause Of Concern: Scientists
4. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
5. Breath to Reveal Presence of Breast Cancer
6. Presence of Beneficial Bacteria in Probiotic Drinks Mere Tall Claims
7. Presence of Pesticides and Metals in Fruits and Vegetable
8. Cancer drugs in development nearly doubled since 1995
9. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
10. African HIV strains more resistant to anti HIV drugs
11. Right drugs drastically cut stroke risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: